Linked Life Data

18496913

Source:http://linkedlifedata.com/resource/pubmed/id/18496913

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:dateCreated
2008-5-22
pubmed:abstractText
Cancer patients, especially those undergoing surgery for cancer, are at extremely high risk for developing venous thromboembolism (VTE), even with appropriate thromboprophylaxis. Anticoagulant prophylaxis in cancer surgery patients has reduced the incidence of VTE events by approximately one-half in placebo-controlled trials, and extended prophylaxis (for up to 1 month) has also significantly reduced out-of-hospital VTE events in clinical trials in this population. Clinical trials show no difference between low-molecular-weight heparin (LMWH) and unfractionated heparin in VTE prophylaxis efficacy or bleeding risk in this population, although the incidence of heparin-induced thrombocytopenia is lower with LMWH. The risk-benefit profile of low-dose anticoagulant prophylaxis appears to be favorable even in many cancer patients undergoing neurosurgery, for whom pharmacologic VTE prophylaxis has been controversial because of bleeding risks.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Apr
pubmed:issn
0891-1150
pubmed:author
pubmed:issnType
Print
pubmed:volume
75 Suppl 3
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S17-26
pubmed:meshHeading
pubmed:year
2008
pubmed:articleTitle
Prevention of venous thromboembolism in the cancer surgery patient.
pubmed:affiliation
Clinical Thrombosis Center, Lovelace Medical Center, Albuquerque, NM 87108, USA. alex.spyropoulos@lovelace.com
pubmed:publicationType
Journal Article, Review